Skip to main content
Evidence Snapshot

Aldo-keto reductase family 1 member C3

CHEMBL4681 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T23:51:42Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4681
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Aldo-keto reductase family 1 member C3 as ChEMBL target CHEMBL4681, mapped to UniProt P42330. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Aldo-keto reductase family 1 member C3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4681
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P42330
Aldo-keto reductase family 1 member C3
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Aldo-keto reductase family 1 member C3 matters

As of 2026-09-13

Aldo-keto reductase family 1 member C3 is reviewed as Aldo-keto reductase family 1 member C3 (UniProt P42330); the current evidence base includes 15 approved drugs, 1103 compounds, and 190 assays, with lead potency reaching pChEMBL 9.5.

Protein context
Aldo-keto reductase family 1 member C3

Aldo-keto reductase family 1 member C3 Sequence length is 323 aa.

Review this target as Aldo-keto reductase family 1 member C3, mapped to UniProt P42330. Sequence length is 323 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt P42330 Protein
Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 15 approved drugs, 1103 compounds, and 190 assays for this target. The dominant activity type is IC50. CHEMBL2413849 is the current potency anchor at pChEMBL 9.5.

Use CHEMBL2413849 as the tractability anchor when discussing potency (pChEMBL 9.5).

Activity source · ChEMBL 36 via Core Engine
15 approved pChEMBL 9.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Aldo-keto reductase family 1 member C3 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P42330, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1103
Total Compounds
190
Total Assays
15
Approved Drugs
IC50: 1319.0, KI: 60.0, KD: 4.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL2413849
9.5 IC50
No preferred name
CHEMBL4110932
9.3 IC50
No preferred name
CHEMBL5821749
9.3 IC50
No preferred name
CHEMBL5823188
9.3 IC50
No preferred name
CHEMBL5830459
9.3 IC50

Approved Drugs

Structure Compound First Approval
GLIMEPIRIDE
CHEMBL1481
1995
FLURBIPROFEN
CHEMBL563
1986
1980
NAPROXEN
CHEMBL154
1976
1967
1965
1959
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T23:51:42Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4681